U.S. puts Canada on watch list over drug-patent policy

05/7/2013 | Financial Post (Canada)

The Office of the U.S. Trade Representative expressed concern over Canada's treatment of pharmaceutical patents in a newly issued report on intellectual-property issues. The trade office placed Canada on its watch list for issues relating to the lack of appeal rights for innovative companies and heightened utility requirements that may violate trade agreements.

View Full Article in:

Financial Post (Canada)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Director of Operations - GBS
Mayo Clinic
Rochester, MN
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Senior Vice President, Clinical Affairs & Strategic Partnerships
America's Health Insurance Plans (AHIP)
Washington, DC